Advertisement
GERN vs TVTX
Which Stock Would AI Choose? Geron Corporation (GERN) vs. Travere Therapeutics (TVTX) Stock Comparison
Key Takeaways
- GERN is a commercial-stage blood-cancer biotech scaling its first approved drug, while TVTX is a rare-kidney-disease specialist riding rapid revenue expansion.
- TVTX has shown markedly stronger relative performance and upward analyst revisions in recent months compared with GERN.
- Both companies remain unprofitable on a net basis, so execution on commercial launches is the central risk for each.
- GERN carries single-product concentration risk around RYTELO, while TVTX has a broader approved and pipeline portfolio.
- Sentiment on TVTX has been supported by regulatory wins and analyst price-target increases, whereas GERN has faced more mixed launch expectations.
- For more detail on the latest developments, visit GERN Major News and GERN Today's Price Move, along with TVTX Major News and TVTX Today's Price Move.
- To see which stocks automated systems currently favor, explore the curated Trending AI Robots page.
Introduction
Geron Corporation (GERN) and Travere Therapeutics (TVTX) are both clinical-to-commercial biopharmaceutical companies, but they operate in different disease areas and have followed sharply different market trajectories. This stock comparison is relevant for investors weighing a single-product blood-cancer launch against a diversified rare-kidney-disease platform, and for traders assessing momentum, volatility, and relative performance. While GERN trades at a low single-digit price with a sub-$1 billion market value, TVTX has re-rated higher on strong revenue growth and regulatory progress. Understanding these contrasts helps clarify each company's market positioning and risk profile.
GERN Overview and Recent Performance
Geron Corporation is a commercial-stage biopharmaceutical company focused on blood cancers, or hematologic malignancies. Its lead product, RYTELO (imetelstat), is a first-in-class telomerase inhibitor approved in the U.S. and European Union for certain adults with lower-risk myelodysplastic syndromes (MDS) and transfusion-dependent anemia. The company is also advancing a Phase 3 trial in relapsed/refractory myelofibrosis.
In recent weeks, GERN has traded in a low single-digit range and has shown elevated volatility, frequently sitting below its 20-day moving average. Recent quarterly results showed year-over-year revenue growth driven by RYTELO uptake, and management issued full-year 2026 net product revenue guidance in the $220 million to $240 million range. However, sentiment has been mixed, as analysts have trimmed price targets on concerns about the pace of commercial execution and single-drug reliance. The stock's relative performance has lagged the broader market, and price movement remains sensitive to launch metrics and pipeline milestones.
TVTX Overview and Recent Performance
Travere Therapeutics is a biopharmaceutical company that develops and delivers therapies for rare kidney and metabolic diseases. Its flagship product, FILSPARI (sparsentan), is approved to slow kidney function decline in IgA nephropathy (IgAN) and to reduce proteinuria in focal segmental glomerulosclerosis (FSGS). The company also markets Thiola for cystinuria and is advancing a pipeline that includes pegtibatinase for classical homocystinuria (HCU).
In recent market activity, TVTX has posted substantial gains, reflecting rapid revenue growth and a series of positive regulatory and clinical developments, including an FDA advisory committee meeting cancellation that boosted approval confidence. Analyst sentiment has strengthened, with multiple firms raising price targets and a consensus rating of Strong Buy. Recent quarterly revenue rose sharply year over year, though the company still reported a net loss. This momentum reflects strong commercial traction for FILSPARI and expanding label opportunities rather than profitability, which remains a key watchpoint.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's AI trading bots. Tickeron maintains hundreds of automated trading bots that monitor thousands of different tickers, each with its own trading style, strategy, timeframe, performance statistics, and target universe. Because market conditions change, only the bots best suited to the current environment earn a place in this featured section. The page highlights key metrics such as historical performance and trade frequency, helping users identify strategies aligned with prevailing trends. Whether you follow momentum, mean reversion, or swing approaches, exploring Trending AI Robots can help you understand how algorithmic systems are currently positioned across the market.
Head-to-Head Comparison
The two companies differ fundamentally in business model and scale. GERN is concentrated in hematology with a single commercial therapy, creating concentrated upside but also single-product risk if launch uptake or safety trends disappoint. TVTX operates across multiple rare kidney and metabolic indications with both approved products and a pipeline, offering broader diversification.
On growth drivers, TVTX benefits from expanding FILSPARI indications and accelerating revenue, while GERN depends on deepening RYTELO penetration and eventual myelofibrosis data. On recent momentum and market sentiment, TVTX has clearly outpaced GERN, with rising price targets versus trimmed estimates. Both face elevated volatility and ongoing cash burn, but TVTX is closer to breakeven on an earnings-per-share basis and carries a substantially larger market capitalization.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would currently lean toward TVTX. The stock exhibits stronger trend consistency, more favorable relative performance, and a catalyst-rich environment driven by regulatory progress, label expansion, and rising analyst targets. GERN shows more mixed positioning, with elevated volatility and cautious commercial expectations tempering its technical profile. This is a probabilistic assessment grounded in momentum and market positioning rather than a definitive prediction, and conditions can shift quickly in both names.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GERN is a StrongBuy and TVTX is a Buy.
GERN sees its Stochastic Oscillator recovers from oversold territory
On November 04, 2026, the Stochastic Oscillator for GERN moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 69 instances where the indicator left the oversold zone. In 58 of the 69 cases the stock moved higher in the following days. This puts the odds of a move higher at over 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where GERN's RSI Indicator exited the oversold zone, 24 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for GERN just turned positive on November 10, 2026. Looking at past instances where GERN's MACD turned positive, the stock continued to rise in 41 of 55 cases over the following month. The odds of a continued upward trend are 75%.
Following a +4.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where GERN advanced for three days, in 165 of 215 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
GERN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GERN as a result. In 90 of 100 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GERN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for GERN entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. GERN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.909) is normal, around the industry mean (3.498). P/E Ratio (-8.998) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (16.670) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (4.250) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GERN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
TVTX's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for TVTX turned positive on October 22, 2026. Looking at past instances where TVTX's MACD turned positive, the stock continued to rise in 37 of 45 cases over the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where TVTX's RSI Indicator exited the oversold zone, 22 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on TVTX as a result. In 78 of 101 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
Following a +4.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where TVTX advanced for three days, in 213 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
TVTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TVTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Aroon Indicator for TVTX entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 35 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 42 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. TVTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: TVTX's P/B Ratio (238.095) is very high in comparison to the industry average of (3.498). P/E Ratio (17.370) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (5.690) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (9.794) is also within normal values, averaging (440.869).
GERN | TVTX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 5 | 29 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 92 Overvalued | 100 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 42 | |
SMR RATING 1..100 | 97 | 99 | |
PRICE GROWTH RATING 1..100 | 79 | 47 | |
P/E GROWTH RATING 1..100 | 14 | 35 | |
SEASONALITY SCORE 1..100 | n/a | 55 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GERN's Valuation (92) in the Biotechnology industry is in the same range as TVTX (100). This means that GERN’s stock grew similarly to TVTX’s over the last 12 months.
TVTX's Profit vs Risk Rating (42) in the Biotechnology industry is somewhat better than the same rating for GERN (100). This means that TVTX’s stock grew somewhat faster than GERN’s over the last 12 months.
GERN's SMR Rating (97) in the Biotechnology industry is in the same range as TVTX (99). This means that GERN’s stock grew similarly to TVTX’s over the last 12 months.
TVTX's Price Growth Rating (47) in the Biotechnology industry is in the same range as GERN (79). This means that TVTX’s stock grew similarly to GERN’s over the last 12 months.
GERN's P/E Growth Rating (14) in the Biotechnology industry is in the same range as TVTX (35). This means that GERN’s stock grew similarly to TVTX’s over the last 12 months.
| GERN | TVTX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 77% | 2 days ago 76% |
| Stochastic ODDS (%) | 2 days ago 84% | 2 days ago 79% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 77% |
| MACD ODDS (%) | 2 days ago 75% | 2 days ago 82% |
| TrendWeek ODDS (%) | 2 days ago 78% | 2 days ago 78% |
| TrendMonth ODDS (%) | 2 days ago 84% | 2 days ago 80% |
| Advances ODDS (%) | 3 days ago 77% | 2 days ago 77% |
| Declines ODDS (%) | 13 days ago 80% | 10 days ago 77% |
| BollingerBands ODDS (%) | 2 days ago 78% | 6 days ago 74% |
| Aroon ODDS (%) | 2 days ago 82% | 2 days ago 80% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GERN’s FA Score shows that 1 FA rating(s) are green while TVTX’s FA Score has 0 green FA rating(s).
- GERN’s FA Score: 1 green, 4 red.
- TVTX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GERN’s TA Score shows that 5 TA indicator(s) are bullish while TVTX’s TA Score has 5 bullish TA indicator(s).
- GERN’s TA Score: 5 bullish, 3 bearish.
- TVTX’s TA Score: 5 bullish, 3 bearish.
Price Growth
GERN (@Biotechnology) experienced а +4.75% price change this week, while TVTX (@Biotechnology) price change was +5.22% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
GERN is expected to report earnings on Mar 03, 2027.
TVTX is expected to report earnings on Feb 25, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| EPEM | 29.52 | N/A | N/A |
| Harbor Emerging Markets Equity ETF | |||
| AKRE | 60.27 | -0.03 | -0.05% |
| Akre Focus ETF (AKRE) | |||
| PSFO | 35.63 | -0.10 | -0.27% |
| Pacer Swan SOS Flex (October) ETF (PSFO) | |||
| PFDE | 26.44 | -0.13 | -0.51% |
| Pathfinder Disciplined US Equity ETF (PFDE) | |||
| NFLT | 22.27 | -0.15 | -0.67% |
| Virtus Newfleet Multi-Sector Bond ETF (NFLT) | |||